Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Prepaid Assets (2020 - 2025)

Insight Molecular Diagnostics' Prepaid Assets history spans 6 years, with the latest figure at $1.2 million for Q3 2025.

  • For Q3 2025, Prepaid Assets rose 97.61% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, up 97.61%, while the annual FY2024 figure was $821000.0, 27.68% up from the prior year.
  • Prepaid Assets for Q3 2025 was $1.2 million at Insight Molecular Diagnostics, down from $1.3 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $2.3 million in Q3 2021 and bottomed at $595000.0 in Q2 2024.
  • The 5-year median for Prepaid Assets is $1.1 million (2022), against an average of $1.2 million.
  • The largest annual shift saw Prepaid Assets skyrocketed 4151.85% in 2021 before it tumbled 69.09% in 2023.
  • A 5-year view of Prepaid Assets shows it stood at $901000.0 in 2021, then increased by 8.44% to $977000.0 in 2022, then plummeted by 34.19% to $643000.0 in 2023, then increased by 27.68% to $821000.0 in 2024, then skyrocketed by 50.91% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Prepaid Assets are $1.2 million (Q3 2025), $1.3 million (Q2 2025), and $1.2 million (Q1 2025).